Clearside Biomedical And 3 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed higher by around 350 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Sabre

• The Trade: Sabre Corporation SABR Executive Vice President Roshan Mendis bought a total of 31,067 shares at an average price of $3.15. To acquire these shares, it cost around $97,802.
• What's Happening: On May 2, Sabre reported better-than-expected first-quarter results and updated FY24 revenue outlook.
• What Sabre Does: Sabre holds the number-two air booking volume share in the global distribution system industry.

Zomedica

• The Trade: Zomedica Corp. ZOM Director Johnny D Powers acquired a total of 50,000 shares at an average price of $0.14. To acquire these shares, it cost around $6,981.
• What's Happening: On May 15, Zomedica announced the launch of Over-the-Air software and firmware update capability for its TRUFORMA point-of-care diagnostic platform..
• What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.

Clearside Biomedical

• The Trade: Clearside Biomedical, Inc. CLSD Director Benjamin R Yerxa acquired a total of 7,813 shares at an average price of $1.31. The insider spent around $10,235 to buy those shares.
• What's Happening: On May 9, Clearside Biomedical reported worse-than-expected first-quarter financial results.
• What Clearside Biomedical Does: Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company.

Lipella Pharmaceuticals

• The Trade: Lipella Pharmaceuticals Inc. LIPO 10% owner Jonathan H Kaufman acquired a total of 10,000 shares at an average price of $0.76. The insider spent around $7,590 to buy those shares.
• What's Happening: On April 17, Lipella Pharmaceuticals expanded its advisory board to include oncology expertise.
• What Lipella Pharmaceuticals Does: Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company.

Read This: Jim Cramer: This Industrial Company Is ‘Absolutely Terrific’, Recommends Buying Modine Manufacturing